Top

Published in:

Open Access 01-12-2015 | Case report

Pancreatic mucinous cystadenoma with serum CA 19–9 over 1,000,000 U/mL: a case report and review of the literature

Authors: Wilson L Costa Jr, Henrique Mantoan, Rafael Horácio Brito, Héber SC Ribeiro, Alessandro L Diniz, André Luís Godoy, Igor Correia Farias, Maria Dirlei FS Begnami, Fernando Augusto Soares, Felipe JF Coimbra

Published in: World Journal of Surgical Oncology | Issue 1/2015

Abstract

Background

The diagnosis of pancreatic cystic neoplasms has become more accurate recently. In some cases, however, doubt remains regarding the lesion’s malignant potential. CA 19–9 has long been identified as a reliable biomarker in differentiating pancreatic benign and malignant lesions, especially in non-jaundiced patients.

Case report and discussion

We report a case of a young female who presented with a mucinous lesion in the tail of the pancreas and a serum CA 19–9 over 1,000,000 U/mL. She was taken to surgery and had a distal pancreatectomy and splenectomy. Pathology reports showed only a mucinous cystadenoma. After 1 year of follow-up, her serum CA 19–9 was normal. Following that, the work-up in these lesions, the role of the biomarker in pancreatic adenocarcinoma and in the differentiation between benign and malignant lesions is discussed.

Jesipowicz J, Piłat J, Jesipowicz M, Matras P, Rudzki S. Late detection, progress and results of treatment of pancreatic cancer. Wspolczesna Onkol. 2000;4:76–9.

Valsangkar NP, Morales-Oyarvide V, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012;152:S4–12.CrossRefPubMedCentralPubMed

Fasanella KE, McGrath K. Cystic lesions and intraductal neoplasms of the pancreas. Best Pract Res Clin Gastroenterol. 2009;23:35–48.CrossRefPubMed

Kwon RS. Advances in the diagnosis of cystic neoplasms of the pancreas. Curr Opin Gastroenterol. 2012;28:494–500.CrossRefPubMed

Roggin KK, Chennat J, Oto A, Noffsinger A, Briggs A, Matthews JB. Pancreatic cystic neoplasm. Curr Probl Surg. 2010;47:459–510.CrossRefPubMed

Allen PJ, D’Angelica M, Gonen M, Jaques DP, Coit DG, Jarnagin WR, et al. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg. 2006;244:572–82.PubMedCentralPubMed

Katz MH, Mortenson MM, Wang H, Hwang R, Tamm EP, Staerkel G, et al. Diagnosis and management of cystic neoplasms of the pancreas: an evidence based approach. J Am Coll Surg. 2008;207:106–20.CrossRefPubMed

Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–5.PubMed

Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Suedo T. Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery. 2006;140:448–53.CrossRefPubMed

10.

Rudnicki J, Agrawal AK, Grzebieniak Z, Zukrowski P, Zysko D, Jelen M, et al. Prognostic value of CA 19–9 level in resectable pancreatic adenocarcinoma. Folia Histochem Cytobiol. 2010;48:249–61.PubMed

11.

Joergensen MT, Brunner N. Schaffalitzky De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res. 2010;2:587–92.

12.

Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MW, Wer-ner J. Role of serum carbohydrate antigen 19–9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98:104–10.CrossRefPubMed

13.

Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg. 2012;256:313–20.CrossRefPubMed

14.

Jones NB, Hatzaras I, George N, Muscarella P, Ellison EC, Melvin WS, et al. Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience. HPB. 2009;11:664–70.CrossRefPubMedCentralPubMed

15.

Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902.CrossRefPubMed

16.

Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226–32.CrossRefPubMed

17.

Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, et al. Carbohydrate antigen 19–9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630–9.CrossRefPubMed

18.

Koprowski H, Brockhaus M, Blaszczyk M, Magnani J, Steplewski Z, Ginsburg V. Lewis blood-type may affect the incidence of gastrointestinal cancer. Lancet. 1982;1:1332–3.CrossRefPubMed

19.

Sarr MG, Schnelldorfer T, Lombardo KMR, Chari ST. Advances in our understanding of cystic neoplasms of the pancreas. Am J Surg. 2007;194:S100–3.CrossRef

20.

God DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, et al. PAM4 enzyme immunoassay alone and in combination with CA 19–9 for the detection of pancreatic adenocarcinoma. Cancer. 2013;119:522–8.CrossRef

21.

Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA 19–9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142–7.CrossRefPubMed

22.

Salvia R, Malleo G, Marchegiani G, Pennachino S, Paiella S, Paini M, et al. Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery. 2012;152:S135–42.CrossRefPubMed

Title: Pancreatic mucinous cystadenoma with serum CA 19–9 over 1,000,000 U/mL: a case report and review of the literature
Authors: Wilson L Costa Jr
Henrique Mantoan
Rafael Horácio Brito
Héber SC Ribeiro
Alessandro L Diniz
André Luís Godoy
Igor Correia Farias
Maria Dirlei FS Begnami
Fernando Augusto Soares
Felipe JF Coimbra
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-015-0476-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pancreatic mucinous cystadenoma with serum CA 19–9 over 1,000,000 U/mL: a case report and review of the literature

Abstract

Background

Case report and discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case report and discussion

Please log in to get access to this content

Other articles of this Issue 1/2015

A case of marginal zone B cell lymphoma mimicking IgG4-related dacryoadenitis and sialoadenitis

Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions

Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma

Implantation of customized 3-D printed titanium prosthesis in limb salvage surgery: a case series and review of the literature

Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report

Transverse colon cancer occurring at a colostomy site 35 years after colostomy: a case report